Barr Laboratories

BRL-N

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about BRL-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
October 24, 2006
(A Top Pick Sept 26/05. Down 7%.) Still likes. Down because the Wal-Mart announcement of putting price pressures on generics. Very innovative company, introducing lots of new products. Acquiring a European company to increase penetration into Europe.
Show full opinionHide full opinion
Barr Laboratories (BRL-N)
October 24, 2006
(A Top Pick Sept 26/05. Down 7%.) Still likes. Down because the Wal-Mart announcement of putting price pressures on generics. Very innovative company, introducing lots of new products. Acquiring a European company to increase penetration into Europe.
PAST TOP PICK
PAST TOP PICK
August 14, 2006
(A Top Pick Sept 26/05. Up 10%.) Still likes and is continuing to buy it here. The big news is the approval of their oral contraceptive.
Show full opinionHide full opinion
(A Top Pick Sept 26/05. Up 10%.) Still likes and is continuing to buy it here. The big news is the approval of their oral contraceptive.
BUY
BUY
July 20, 2006
Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.
Show full opinionHide full opinion
Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.
PAST TOP PICK
PAST TOP PICK
May 17, 2006
(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.
Show full opinionHide full opinion
(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.
TOP PICK
TOP PICK
May 3, 2006
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
Show full opinionHide full opinion
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
TOP PICK
TOP PICK
March 15, 2006
Barr Pharma is a generic manufacturer. Good match with a large cap drug company. Barr is a very good company. Strong balance sheet. Started buying at $47-48 range and are still buying.
Show full opinionHide full opinion
Barr Pharma is a generic manufacturer. Good match with a large cap drug company. Barr is a very good company. Strong balance sheet. Started buying at $47-48 range and are still buying.
TOP PICK
TOP PICK
September 26, 2005
A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
Show full opinionHide full opinion
Barr Laboratories (BRL-N)
September 26, 2005
A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
BUY
BUY
July 19, 2005
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. A generic manufacturer. As more and more drugs come off patent, this is a good way to take advantage of the increasing demand for drugs.
Show full opinionHide full opinion
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. A generic manufacturer. As more and more drugs come off patent, this is a good way to take advantage of the increasing demand for drugs.
TOP PICK
TOP PICK
June 20, 2005
A generic drug manufacturer. Going to continue to grow at 15/20% over the next 3/5 years. There's a number of drugs coming off patent over the next 2/3 years and this company is probably the best positioned to benefit. Good price.
Show full opinionHide full opinion
A generic drug manufacturer. Going to continue to grow at 15/20% over the next 3/5 years. There's a number of drugs coming off patent over the next 2/3 years and this company is probably the best positioned to benefit. Good price.
BUY WEAKNESS
BUY WEAKNESS
July 17, 2003
Generic drugs is a great sector. Accumulate on a gradual basis.
Show full opinionHide full opinion
Generic drugs is a great sector. Accumulate on a gradual basis.
DON'T BUY
DON'T BUY
April 10, 2002
Health sector has been under a lot of pressure. Prefers specialty pharmaceuticals.
Show full opinionHide full opinion
Health sector has been under a lot of pressure. Prefers specialty pharmaceuticals.
Showing 1 to 11 of 11 entries
  • «
  • 1
  • »

Barr Laboratories(BRL-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Barr Laboratories is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Barr Laboratories(BRL-N) Frequently Asked Questions

What is Barr Laboratories stock symbol?

Barr Laboratories is a OTC stock, trading under the symbol BRL-N on the (). It is usually referred to as or BRL-N

Is Barr Laboratories a buy or a sell?

In the last year, there was no coverage of Barr Laboratories published on Stockchase.

Is Barr Laboratories a good investment or a top pick?

Barr Laboratories was recommended as a Top Pick by Laura Wallace on 2006-10-24. Read the latest stock experts ratings for Barr Laboratories.

Why is Barr Laboratories stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Barr Laboratories worth watching?

In the last year 0 stock analysts on Stockchase covered Barr Laboratories. The stock is worth watching.

What is Barr Laboratories stock price?

On , Barr Laboratories (BRL-N) stock closed at a price of $.